Derived from follicular epithelial cells, differentiated thyroid cancer (DTC) accounts for the
majority of thyroid malignancies. The threefold increase in DTC incidence over the last three …

The spectrum of thyroid cancers ranges from one of the most indolent to one of the most
aggressive solid tumors identified. Conventional therapies for thyroid cancers are based on …

The concept of individualized therapy is rapidly gaining recognition in the management of
patients with differentiated thyroid cancer (DTC). This Review provides an overview of the …

Therapeutic options for advanced, unresectable radioiodine-resistant thyroid cancers have
historically been limited. Recent progress in understanding the pathogenesis of the various …

Differentiated thyroid cancer, which includes papillary and follicular histologies, is a common
malignancy and is increasing in incidence. It carries a favorable prognosis compared to …

Advanced differentiated thyroid cancer (DTC), defined by clinical characteristics including
gross extrathyroidal invasion, distant metastases, radioiodine (RAI) resistance, and avidity …

The vast majority of patients with differentiated thyroid cancer (DTC) are treated successfully
with surgery and radioactive iodine ablation, yet the treatment of advanced cases is …

Differentiated thyroid carcinoma (DTC) accounts for more than 90% of new thyroid cancer
diagnoses, and includes papillary, follicular and Hürthle cell carcinoma. The prognosis for …

Differentiated thyroid cancer (DTC) is the most common endocrine malignancy. The
standard treatment for DTC includes surgery, radioiodine ablation, and thyroid hormone …

Differentiated thyroid carcinomas (DTCs) that arise from follicular cells account> 90% of
thyroid cancer (TC)[papillary thyroid cancer (PTC) 90%, follicular thyroid cancer (FTC) 10%] …